Completed PHASE3 INTERVENTIONAL NCT00002224

Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

Comparison of HIV RNA Suppression Produced by Triple Regimens Containing Either Didanosine Enteric Coated or Didanosine Formulations Each Administered Once Daily

Sponsor: Bristol-Myers Squibb

Conditions HIV Infections

Interventions Didanosine Nelfinavir mesylate Stavudine

Updated 8 times since 2017 Last updated: Apr 13, 2011 Started: Mar 31, 1999 Primary completion: Mar 31, 1999 Completion: Mar 31, 1999

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on HIV Infections, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 8 data snapshots since 1999. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Birmingham, United States , Boulder, United States , Chicago, United States , Dallas, United States , Fort Lauderdale, United States , Houston, United States , Las Vegas, United States , Los Angeles, United States , Miami, United States and 9 more locations